An Analysis of the Results of the BETH Study
Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the results of the BETH study
Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the results of the BETH study, which compared chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus bevacizumab in patients with HER2-positive breast cancer.
Clinical Pearls:
- Although the results of the trial were negative, the results did show that THC therapy is as good, if not better, than ACTH therapy
- The results of the BETH study are consistent with other studies
- The era of adjuvant bevacizumab for breast cancer has come and gone unless there is a way to select patients who will benefit
- Some biomarkers are in the works that may be able to be used to select patients who will benefit from bevacizumab
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
